The Procter & Gamble Company (PG) Spending and interest coverage
- R&D / revenue · 12 months: Value 2.41%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.60%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2.41% | Research and development expense / revenue. Period ending 2026-06-30. $2.10B ÷ $87.03B × 100 ≈ 2.41% |
| Stock-based compensation / revenue · 12 months | 0.60% | Share-based compensation / revenue. Period ending 2026-06-30. $524.00M ÷ $87.03B × 100 ≈ 0.60% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 2.10B USD | Research and Development Expense |
| Revenue | 87.03B USD | |
| Stock-based compensation | 524.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 19.75B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.10B | $87.03B | $524.00M | $19.75B | (m) | 2.41% | 0.60% | (m) | (m) |
| 2026-03-31 | (m) | $86.72B | $506.00M | $20.15B | (m) | (m) | 0.58% | (m) | (m) |
| 2025-12-31 | (m) | $85.26B | $497.00M | $20.14B | (m) | (m) | 0.58% | (m) | (m) |
| 2025-09-30 | (m) | $84.93B | $492.00M | $20.51B | (m) | (m) | 0.58% | (m) | (m) |
| 2025-06-30 | $2.10B | $84.28B | $476.00M | $20.45B | (m) | 2.49% | 0.56% | (m) | (m) |
| 2025-03-31 | (m) | $83.93B | $493.00M | $19.98B | (m) | (m) | 0.59% | (m) | (m) |
| 2024-12-31 | (m) | $84.35B | $528.00M | $19.88B | (m) | (m) | 0.63% | (m) | (m) |
| 2024-09-30 | (m) | $83.91B | $542.00M | $18.57B | (m) | (m) | 0.65% | (m) | (m) |
| 2024-06-30 | $2.00B | $84.04B | $562.00M | $18.55B | (m) | 2.38% | 0.67% | (m) | (m) |
| 2024-03-31 | (m) | $84.06B | $572.00M | $18.82B | $945.00M | (m) | 0.68% | 19.92× | Reported |
| 2023-12-31 | (m) | $83.93B | $570.00M | $18.61B | $934.00M | (m) | 0.68% | 19.93× | Reported |
| 2023-09-30 | (m) | $83.27B | $565.00M | $18.96B | $858.00M | (m) | 0.68% | 22.10× | Reported |
| 2023-06-30 | $2.00B | $82.01B | $545.00M | $18.13B | $756.00M | 2.44% | 0.66% | 23.99× | Reported |
| 2023-03-31 | (m) | $80.97B | $536.00M | $17.57B | $631.00M | (m) | 0.66% | 27.84× | Reported |
| 2022-12-31 | (m) | $80.28B | $510.00M | $17.35B | $518.00M | (m) | 0.64% | 33.49× | Reported |
| 2022-09-30 | (m) | $80.46B | $517.00M | $17.73B | $453.00M | (m) | 0.64% | 39.14× | Reported |
| 2022-06-30 | $2.00B | $80.19B | $528.00M | $17.81B | $439.00M | 2.49% | 0.66% | 40.58× | Reported |
| 2022-03-31 | (m) | $79.62B | $540.00M | $17.75B | $441.00M | (m) | 0.68% | 40.26× | Reported |
| 2021-12-31 | (m) | $78.35B | $554.00M | $17.52B | $438.00M | (m) | 0.71% | 39.99× | Reported |
| 2021-09-30 | (m) | $77.14B | $567.00M | $17.73B | $475.00M | (m) | 0.74% | 37.32× | Reported |
| 2021-06-30 | $1.90B | $76.12B | $540.00M | $17.99B | $502.00M | 2.50% | 0.71% | 35.83× | Reported |
| 2021-03-31 | (m) | $74.87B | $631.00M | $17.93B | $542.00M | (m) | 0.84% | 33.08× | Reported |
| 2020-12-31 | (m) | $73.97B | $610.00M | $17.59B | $536.00M | (m) | 0.82% | 32.83× | Reported |
| 2020-09-30 | (m) | $72.47B | $537.00M | $16.70B | $493.00M | (m) | 0.74% | 33.87× | Reported |
| 2020-06-30 | $1.80B | $70.95B | $558.00M | $15.71B | $465.00M | 2.54% | 0.79% | 33.78× | Reported |
| 2020-03-31 | (m) | $70.35B | $541.00M | $7.03B | $419.00M | (m) | 0.77% | 16.79× | Reported |
| 2019-12-31 | (m) | $69.59B | $536.00M | $6.81B | $450.00M | (m) | 0.77% | 15.13× | Reported |
| 2019-09-30 | (m) | $68.79B | $523.00M | $6.22B | $488.00M | (m) | 0.76% | 12.75× | Reported |
| 2019-06-30 | $1.90B | $67.68B | $515.00M | $5.49B | $509.00M | 2.81% | 0.76% | 10.78× | Reported |
| 2019-03-31 | (m) | $67.09B | $445.00M | $13.27B | $534.00M | (m) | 0.66% | 24.84× | Reported |
| 2018-12-31 | (m) | $66.91B | $419.00M | $13.25B | $536.00M | (m) | 0.63% | 24.71× | Reported |
| 2018-09-30 | (m) | $66.87B | $413.00M | $13.62B | $520.00M | (m) | 0.62% | 26.19× | Reported |
| 2018-06-30 | $1.90B | $66.83B | $395.00M | $13.71B | $506.00M | 2.84% | 0.59% | 27.10× | Reported |
| 2018-03-31 | (m) | $66.41B | $403.00M | $13.98B | $486.00M | (m) | 0.61% | 28.77× | Reported |
| 2017-12-31 | (m) | $65.73B | $404.00M | $14.05B | $449.00M | (m) | 0.61% | 31.29× | Reported |
| 2017-09-30 | (m) | $65.19B | $391.00M | $13.92B | $449.00M | (m) | 0.60% | 31.00× | Reported |
| 2017-06-30 | $1.90B | $65.06B | $351.00M | $13.96B | $465.00M | 2.92% | 0.54% | 30.01× | Reported |
| 2017-03-31 | (m) | $65.08B | $316.00M | $13.51B | $499.00M | (m) | 0.49% | 27.07× | Reported |
| 2016-12-31 | (m) | $65.23B | $299.00M | $13.47B | $549.00M | (m) | 0.46% | 24.53× | Reported |
| 2016-09-30 | (m) | $65.29B | $312.00M | $13.44B | $570.00M | (m) | 0.48% | 23.59× | Reported |
| 2016-06-30 | $1.90B | $65.30B | $335.00M | $13.44B | $579.00M | 2.91% | 0.51% | 23.21× | Reported |
| 2016-03-31 | (m) | $65.75B | $322.00M | $11.75B | $577.00M | (m) | 0.49% | 20.37× | Reported |
| 2015-12-31 | (m) | $66.92B | $326.00M | $11.46B | $579.00M | (m) | 0.49% | 19.79× | Reported |
| 2015-09-30 | (m) | $74.03B | $323.00M | $11.93B | $596.00M | (m) | 0.44% | 20.01× | Reported |
| 2015-06-30 | $2.00B | $76.28B | $337.00M | $11.79B | $626.00M | 2.62% | 0.44% | 18.83× | Reported |
| 2015-03-31 | (m) | (m) | $344.00M | $14.57B | $657.00M | (m) | (m) | 22.18× | Reported |
| 2014-12-31 | (m) | (m) | $358.00M | $14.74B | $688.00M | (m) | (m) | 21.43× | Reported |
| 2014-09-30 | (m) | (m) | $357.00M | $14.11B | $713.00M | (m) | (m) | 19.79× | Reported |
| 2014-06-30 | $2.00B | (m) | $360.00M | $15.29B | $709.00M | (m) | (m) | 21.56× | Reported |
| 2014-03-31 | (m) | $84.70B | $343.00M | $14.79B | $694.00M | (m) | 0.40% | 21.32× | Reported |
| 2013-12-31 | (m) | $84.74B | $345.00M | $14.74B | $678.00M | (m) | 0.41% | 21.74× | Reported |
| 2013-09-30 | (m) | $84.63B | $351.00M | $14.68B | $660.00M | (m) | 0.41% | 22.24× | Reported |
| 2013-06-30 | $2.00B | $84.17B | $346.00M | $14.48B | $667.00M | 2.38% | 0.41% | 21.71× | Reported |
| 2013-03-31 | (m) | $83.72B | $350.00M | $14.91B | $686.00M | (m) | 0.42% | 21.74× | Reported |
| 2012-12-31 | (m) | $83.32B | $363.00M | $14.80B | $702.00M | (m) | 0.44% | 21.09× | Reported |
| 2012-09-30 | (m) | $82.89B | $376.00M | $12.99B | $734.00M | (m) | 0.45% | 17.70× | Reported |
| 2012-06-30 | (m) | $83.68B | $377.00M | $13.29B | $769.00M | (m) | 0.45% | 17.28× | Reported |
| 2012-03-31 | (m) | $85.37B | $396.00M | $13.73B | $799.00M | (m) | 0.46% | 17.19× | Reported |
| 2011-12-31 | (m) | $85.14B | $402.00M | $14.13B | $822.00M | (m) | 0.47% | 17.19× | Reported |
| 2011-09-30 | (m) | $84.35B | $407.00M | $15.65B | $830.00M | (m) | 0.48% | 18.86× | Reported |
| 2011-06-30 | (m) | $82.56B | $414.00M | $15.82B | $831.00M | (m) | 0.50% | 19.03× | Reported |
| 2011-03-31 | (m) | $80.63B | $415.00M | $15.48B | $831.00M | (m) | 0.51% | 18.63× | Reported |
| 2010-12-31 | (m) | $79.57B | $428.00M | $15.68B | $852.00M | (m) | 0.54% | 18.40× | Reported |
| 2010-09-30 | (m) | $79.25B | $441.00M | $16.07B | $867.00M | (m) | 0.56% | 18.54× | Reported |
| 2010-06-30 | (m) | $78.94B | $453.00M | $16.02B | $946.00M | (m) | 0.57% | 16.94× | Reported |
| 2010-03-31 | (m) | $78.10B | $481.00M | $16.45B | $1.06B | (m) | 0.62% | 15.49× | Reported |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | $76.69B | $516.00M | $15.37B | $1.36B | (m) | 0.67% | 11.32× | Reported |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | $79.26B | $555.00M | $15.98B | $1.47B | (m) | 0.70% | 10.89× | Reported |
| 2007-06-30 | (m) | $72.44B | $668.00M | $14.48B | $1.30B | (m) | 0.92% | 11.11× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ECOLAB INC. (ECL) | United States | $77.183B | 36.58 |
| CHURCH & DWIGHT CO INC /DE/ (CHD) | United States | $22.622B | 30.81 |
| STEPAN CO (SCL) | United States | $1.451B | -477.05 |
| Longevity Health Holdings, Inc. (XAGE) | United States | $0.006B | -0.09 |